Brought to you by 
Elan acquires Dura Pharmaceuticals for $1.69bn
Sep 2000
Executive Summary
Elan has acquired Dura Pharmaceuticals (respiratory pharmaceuticals) in a tax-free, stock-for-stock transaction valued at $1.69bn. Dura shareholders will receive 0.6715 of an Elan ADS in exchange for one share, or $37.85, a (pr)38% premium based on the market average.
Deal Industry
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elan acquires Dura Pharmaceuticals for $1.69bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice